Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Acta Virol ; 65(4): 420-432, 2021.
Article in English | MEDLINE | ID: covidwho-1526914

ABSTRACT

Cross-sectional seroprevalence study of SARS-CoV-2 IgG antibodies was accomplished in the Slovak Academy of Sciences to inform authorities of research institutions about the situation at their workplaces, to assess the risk of next exposure to SARS-CoV-2, and to guide decisions on institutional measures sustaining essential research in evolving epidemic situation. Study participants provided informed consent, anamnestic information, and self-collected dry blood spot samples that were analyzed by ELISA for SARS-CoV-2 S protein-specific IgG antibodies. Relative antibody levels detected in 1928 subjects showed seroprevalence of 84.13% and led to the following main findings consistent with the current knowledge: (1) mRNA-based vaccines induce better humoral response compared to adenovirus vaccines, (2) antibody levels reflect severity of COVID-19 symptoms, (3) post-COVID vaccination results in marked elevation of IgG levels particularly in asymptomatic and mild cases, (4) antibody levels decrease with increasing time elapsed from vaccination or COVID-19. In addition, data sorting to distinct research institutes and their clustering to three principal scientific sections of the Slovak Academy of Sciences revealed marked differences in seroprevalence, and allowed to identify workplaces with relatively high seropositivity and response rate that can potentially provide a safer working environment than those, where seroprevalence was low or unknown due to low participation. Thus, findings of this study can have direct implications on management decisions during the next pandemic development, with the necessity to keep in mind the phenomenon of time-dependent immunity waning and current spread of more contagious Delta variant of SARS-CoV-2. Keywords: SARS-CoV-2 coronavirus; COVID-19; spike protein; seroprevalence; antibodies; vaccination.


Subject(s)
COVID-19 , Academies and Institutes , Antibodies, Viral , Cross-Sectional Studies , Humans , Immunoglobulin G , SARS-CoV-2 , Seroepidemiologic Studies , Slovakia/epidemiology , Spike Glycoprotein, Coronavirus , Vaccination
2.
PLoS One ; 16(8): e0256669, 2021.
Article in English | MEDLINE | ID: covidwho-1372021

ABSTRACT

We study geographical epidemic scales and patterns and positivity trends of SARS-CoV-2 pandemics in mass antigen testing in Slovakia in 2020. The observed test positivity was exponentially distributed with a long scale exponential spatial trend, and its characteristic correlation length was approximately 10 km. Spatial scales also play an important role in test positivity reduction between two consecutive testing rounds. While test positivity decreased in all counties, it increased in individual municipalities with low test positivity in the earlier testing round in a way statistically different from a mean-reversion process. Also, non-residents testing influences the mass testing results as test positivity of non-residents was higher than of residents when testing was offered only in municipalities with the highest positivity in previous rounds. Our results provide direct guidance for pandemic geographical data surveillance and epidemic response management.


Subject(s)
Antigens, Viral/analysis , COVID-19/diagnosis , SARS-CoV-2/metabolism , COVID-19/epidemiology , COVID-19/virology , COVID-19 Serological Testing , Enzyme-Linked Immunosorbent Assay , Humans , Pandemics , SARS-CoV-2/isolation & purification , Slovakia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL